- Home
- ELLO vs SGHT Comparison
ELLO vs SGHT Comparison
Compare ELLO & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- SGHT
- Stock Information
- Founded
- ELLO 1987
- SGHT 2011
- Country
- ELLO Israel
- SGHT United States
- Employees
- ELLO N/A
- SGHT N/A
- Industry
- ELLO Electric Utilities: Central
- SGHT Medical Specialities
- Sector
- ELLO Utilities
- SGHT Health Care
- Exchange
- ELLO Nasdaq
- SGHT Nasdaq
- Market Cap
- ELLO 222.3M
- SGHT 179.7M
- IPO Year
- ELLO 1995
- SGHT 2021
- Fundamental
- Price
- ELLO $18.58
- SGHT $4.06
- Analyst Decision
- ELLO
- SGHT Buy
- Analyst Count
- ELLO 0
- SGHT 8
- Target Price
- ELLO N/A
- SGHT $4.29
- AVG Volume (30 Days)
- ELLO 4.4K
- SGHT 119.4K
- Earning Date
- ELLO 09-29-2025
- SGHT 08-07-2025
- Dividend Yield
- ELLO N/A
- SGHT N/A
- EPS Growth
- ELLO N/A
- SGHT N/A
- EPS
- ELLO 0.43
- SGHT N/A
- Revenue
- ELLO $44,405,534.00
- SGHT $76,303,000.00
- Revenue This Year
- ELLO N/A
- SGHT N/A
- Revenue Next Year
- ELLO N/A
- SGHT $11.32
- P/E Ratio
- ELLO $46.38
- SGHT N/A
- Revenue Growth
- ELLO N/A
- SGHT N/A
- 52 Week Low
- ELLO $11.30
- SGHT $2.03
- 52 Week High
- ELLO $20.81
- SGHT $7.03
- Technical
- Relative Strength Index (RSI)
- ELLO 62.47
- SGHT 53.48
- Support Level
- ELLO $17.30
- SGHT $4.01
- Resistance Level
- ELLO $17.55
- SGHT $4.25
- Average True Range (ATR)
- ELLO 0.47
- SGHT 0.16
- MACD
- ELLO 0.03
- SGHT -0.01
- Stochastic Oscillator
- ELLO 78.43
- SGHT 18.18
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.